2017: A Year in Transition
"HCV Next" features cutting edge news on the latest HCV research developments. With in-depth articles on a range of topics; diagnosis, hepatitis c treatment regimens, side effects, drug/drug interaction, guidelines, practice management issues, to name a few.
The following articles appeared in the January 2017 print edition of HCV NEXT, provided online at Healio.
The following articles appeared in the January 2017 print edition of HCV NEXT, provided online at Healio.
Cover Story
2017: A Year in Transition
Cover Story
2017: A Year in Transition
Cover Story
Throughout 2016, the remarkable success of direct-acting agents was confirmed and extended. Several new drugs — including Epclusa (Gilead), Zepatier (Merck), Daklinza (Bristol-Myers Squibb), Technivie (AbbVie), Viekira Pak (AbbVie) and Viekira XR (AbbVie) — were approved, representing continued remarkable potency of the DAA agents with the added bonus of extension into more pangenotypic activity. While there are still many other new drugs in development with the same trend toward increased potency and pangenotypic activity, it seems that drug development is starting to plateau. This ultimately will leave us with a strong armamentarium from which to choose the best agents for each of our individual patients.
Guest Editorial
New HCV Study Underscores Risk for Human Suffering, Need for Clinician Vigilance
Carol L. Brosgart, MD
In the Journals
HCV Reinfection Common in MSM With HIV
Only 35% of Baby Boomers Diagnosed With HCV in ED Linked to Care
SVR Post–Interferon-Based Therapy Reduces, not Eliminates Risk for HCC
Sovaldi-Based HCV Drugs can Interact Adversely With Common HIV Drug
Canadian Patients With HCV Often Restricted From DAA Treatment
Epclusa Most Effective for HCV Genotype 3 vs. Other DAAs
New HCV Study Underscores Risk for Human Suffering, Need for Clinician Vigilance
Carol L. Brosgart, MD
In the Journals
HCV Reinfection Common in MSM With HIV
Only 35% of Baby Boomers Diagnosed With HCV in ED Linked to Care
SVR Post–Interferon-Based Therapy Reduces, not Eliminates Risk for HCC
Sovaldi-Based HCV Drugs can Interact Adversely With Common HIV Drug
Canadian Patients With HCV Often Restricted From DAA Treatment
Epclusa Most Effective for HCV Genotype 3 vs. Other DAAs
Trend Watch
Gilead Submits NDA for Investigational Treatment of HCV
Expanded Access to Syringe Service Programs Needed to Limit HCV, HIV Infections
FDA Approves Roche’s Cobas MPX Test for use With Cobas 6800/8800 Systems
Gilead Submits NDA for Investigational Treatment of HCV
Expanded Access to Syringe Service Programs Needed to Limit HCV, HIV Infections
FDA Approves Roche’s Cobas MPX Test for use With Cobas 6800/8800 Systems
No comments:
Post a Comment